For the quarter ending 2026-03-31, ALLO has $395,958K in assets. $117,083K in debts. $30,309K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 30,309 | 51,688 | 37,815 | 52,332 |
| Short-term investments | 236,577 | 198,522 | 214,379 | 220,788 |
| Prepaid expenses and other current assets | 6,407 | 7,539 | 8,525 | 9,535 |
| Total current assets | 273,293 | 257,749 | 260,719 | 282,655 |
| Long-term investments | 0 | 8,043 | 24,944 | 29,510 |
| Operating lease right-of-use asset | 38,819 | 39,888 | 40,935 | 41,966 |
| Property and equipment, net | 70,023 | 72,839 | 75,896 | 78,858 |
| Deposit placed in escrow | 0 | 23,479 | 23,472 | 23,484 |
| Restricted cash | 10,292 | 10,292 | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 | 3,513 | 3,828 |
| Total assets | 395,958 | 415,905 | 439,771 | 470,593 |
| Accounts payable | 4,933 | 4,270 | 3,699 | 4,851 |
| Accrued and other current liabilities | 23,397 | 28,244 | 28,134 | 26,824 |
| Total current liabilities | 28,330 | 32,514 | 31,833 | 31,675 |
| Lease liability, noncurrent | 72,633 | 75,045 | 77,134 | 79,241 |
| Other long-term liabilities | 16,120 | 15,804 | 15,475 | 15,116 |
| Total liabilities | 117,083 | 123,363 | 124,442 | 126,032 |
| Common stock, 0.001 par value 400,000,000 shares authorized as of march31, 2026 and december31, 2025 244,816,413 and 229,413,523 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 245 | 229 | 223 | 220 |
| Additional paid-in capital | 2,332,129 | 2,302,753 | 2,286,770 | 2,274,885 |
| Accumulated deficit | -2,053,316 | -2,010,709 | -1,971,899 | -1,930,499 |
| Accumulated other comprehensive income (loss) | -183 | 269 | 235 | -45 |
| Total stockholders equity | 278,875 | 292,542 | 315,329 | 344,561 |
| Total liabilities and stockholders equity | 395,958 | 415,905 | 439,771 | 470,593 |
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)